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There can be no doubt that HIV/AIDS care has
dramatically improved in most correctional facil-
ities since the time when the high prevalence of
HIV in these settings was first recognized. Many
correctional HIV providers still recall early strug-
gles to bring HIV treatment "up to par" in prisons
and jails, and have witnessed or actively partic-
ipated in the gradual improvement of HIV med-
ication access, distribution, and monitoring that
has taken place over the past decade. 
Given that so much has been accomplished in a
relatively short period of time, a common opin-
ion among correctional healthcare providers
familiar with HIV care in correctional settings is
that the facilities now provide care at or above
the national standards of care. But how does
correctional HIV care really measure up? 
Defining current standards of HIV/AIDS care is
a complicated problem. There are, arguably, an
infinite number of factors that contribute to high-
quality medical care. Not all factors can be mea-
sured easily or well. Furthermore, advances in
and recommendations about treatment are con-
stantly evolving as knowledge of the disease
grows. Most HIV experts incorporate advances
into their HIV treatment plans as they are dis-
covered. Further, high-quality HIV care must be
readily accessible to patients, continuous in its
scope, and integrated into existing health care
structures.1
Clinicians who provide HIV/AIDS care in the
correctional setting often lack adequate clinical
space, information technology (computers,
PDAs, electronic medical records, etc.), ready
access to diagnostic studies (lab work, imaging
studies, etc.), access to medical specialists, and
continuing medical education.  In addition, secu-
rity measures often impede the delivery of care,
and patients have multiple co-morbidities such
as mental health problems and substance use.
The HIV Standard
Despite the inherent complexities in doing so,
defining a standard of HIV/AIDS care is essen-
tial to ensuring that comprehensive care is avail-
able to the populations that need it most.
Access to potent combination antiretroviral ther-
apy (also called HAART), medical providers
well-versed in the management of HIV infection,
clinical tests, and a variety of HIV-related ser-
vices are critical components of HIV care. A
range of definitions and descriptions for the
standard of HIV care have been devised; most
include the elements described in Table 1.2-15
We conducted a qualitative research project to
explore HIV care and services available in cor-
rectional settings. The goal of this study was to
examine the care that U.S. correctional facilities
provide for HIV-infected inmates, and to com-
pare this care to that provided by community
clinics to previously-incarcerated individuals.
Methodology
During the National Commission on
Correctional Health Care (NCCHC) Conference
in Denver, Colorado from October 8-12, 2005,
correctional healthcare providers including
physicians, registered nurses, nurse practition-
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ers, administrators, and other individuals
involved with the delivery of HIV care to
incarcerated individuals were surveyed
about the quality of HIV care provided at
the facilities where they were employed.
The survey was one page long, included 23
items, and was completed anonymously
and in writing.
The survey was designed to evaluate mea-
sures of the standard of HIV care that had
been previously described in the published
literature. These measures included the
availability of HAART, access to
expert/specialist care, availability of specif-
ic clinical tests (CD4+ cell count and HIV
viral load assays) and HIV-related ancillary
services. To protect the anonymity of the
corrections-based respondents, data on
type of facility (i.e. jail or prison) at which
they worked was not collected, although
information on the state where their facility
was located was asked. The survey forms
were distributed at a pre-conference semi-
nar prior to the national correctional health
care meeting and also during the confer-
ence. Ninety-nine surveys were completed.
The same 23-item survey was then admin-
istered, via telephone, to healthcare
providers involved with community-based
HIV care. To determine which community-
based healthcare workers should be
included in the survey, individuals directly
involved with correctional healthcare in the
states representative of the majority of the
survey respondents were contacted and
asked to identify clinics in their respective
geographic regions that provided HIV care
to the ex-incarcerated population.
Specifically, these correctional healthcare
workers were asked, "Where do your HIV-
infected inmates go to receive HIV care
upon being released from jail or prison?"
This information was solicited in an attempt
to ensure that the demographics of the
HIV-infected corrections- and community-
based populations would be similar. 
Telephone calls were then made to clinics
located in more than 50 community-based
sites (hospitals, private clinics, and public
clinics) named by correctional healthcare
workers. Thirty individuals representing 30
community-based clinics completed the
survey over the telephone. 
The goal of this study was to provide a sub-
jective "snapshot" of HIV care in correction-
al facilities in 2005, to compare the type of
care and ancillary services available in cor-
rectional facilities and in the communities to
which inmates returned, and to identify,
based on this limited survey, areas of
potential improvement for corrections-
based HIV healthcare. Formal statistical
tests were not performed given the small
sample size and the qualitative nature of
the data.  This study received approval
from the Brown University Institutional
Review Board.
Results
With few exceptions, the polled respon-
dents felt that the HIV care available in
community-based clinics and hospitals sur-
passed that which was available to inmates
in correctional facilities. These respondents
also reported that the four essential com-
ponents of HIV care, as defined in Table 1.
were not as widely available in correctional
settings as they were reported to be in
community-based clinics. One measure on
which correctional facilities, in the respon-
dents' perception, might outperform com-
munity-based clinics was the perceived
availability of substance abuse and mental
health counseling in corrections. 
Expert/Specialist Care
One of the requirements for HIV expertise,
as defined by the HIV Medicine
Association, is whether the clinician is
responsible for the care of at least 25 HIV
patients during the course of a year. This
definition is based on published data
demonstrating improved outcomes for 
patients cared for by HIV "experts" with this
minimal patient load.1,16
For this survey, we used 30 patients as the
cut-off for "experienced" care. Fewer indi-
viduals involved with corrections-based
HIV care were caring for 30 or more HIV
patients at the time they were surveyed,
compared to those providing community-
based care (Figure 1). Respondents pro-
viding corrections-based care also reported
fewer years spent caring for HIV infected
individuals as compared to community-
based respondents, with only 34% having
spent >12 years providing HIV care versus
50% of community providers (Figure 2).
In addition, according to 38% of correction-
al care providers surveyed, an HIV special-
ist was "never" available to see patients at
the facility where they worked, whereas
none of respondents involved with commu-
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TABLE 1: ESSENTIAL COMPONENTS FOR THE STANDARD OF HIV CARE IN THE COMMUNITY
HAART Drug availability; continuity of treatment regimen
Level of expertise as based upon number of years treating HIV
patients and number of HIV patients being treated currently; most
would accept full-time responsibility for >25 patients per year as
indicative of "HIV expertise"
HIV resistance testing; viral load; CD4+ cell count 
Mental health counseling, substance abuse counseling, adher-
ence counseling, dietary/nutritional counseling, HIV education,
HIV case management, etc. 
Expert/specialist care
Clinical tests
Additional HIV
related services
Figure 1. Level of HIV care 
Figure 2. Number of years providing
HIV care 
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Dear Corrections Colleagues,
This month, David Wohl brings us some highlights from the recent Conference on Retroviruses
and Opportunistic Infections. And in our main article, Bernard, Sueker, Colton, Paris, and
DeGroot report some fascinating information from their survey comparing health care available
to incarcerated HIV infected persons to that offered in the free community. Although the study
has a small sample size, it does illuminate some important disparities in access to essential
diagnostic studies such as CD4 counts, HIV viral loads, and HIV resistance testing. Additionally,
this survey documents the wide chasm that often exists between HIV treaters in the free com-
munity and their compatriots inside jails and prisons.  Both groups have significant misconcep-
tions about what is available for their patients on the other side of the fence. Clearly, there is a
need for improved communication and collaboration between correctional public health clini-
cians and those working in free world public health.  Although we provide care to many of the
same patients, it is as if we exist in different dimensions and as a result our patients suffer from
lack of continuity of care.
It is inexcusable that more than twenty years into the HIV epidemic, too many correctional clin-
icians are operating without the essential tools required to provide basic HIV care.  The reality
is that it is not just HIV care that is compromised. It is extraordinarily challenging to meet the
"community standard" when some asthmatics cannot keep inhalers on their persons and most
cannot keep personal peak flow meters (all available models have a steel rod inside, a poten-
tial weapon), many diabetics do not have access to appropriate dietary choices, most hyper-
tensive inmates cannot keep blood pressure cuffs for self monitoring, some patients with angi-
na are not allowed to keep sublingual nitroglycerin in their cells, many correctional systems have
overly restrictive exclusionary policies for hepatitis C treatment, and many jails and prisons
obstruct access to narcotics for the treatment of chronic pain.
Furthermore, correctional clinicians often spend less time dealing with true medical issues than
they do authorizing or denying a myriad of paramedical items such as low bunks, pillows, hats,
gloves, sunglasses, non-wool blankets, shaving exemptions, ice, showers, canes, crutches,
walkers, etc. Many clinicians endure professional isolation while struggling in "clinics" that lack
sinks, exam tables, common implements for examinations, computers, internet access, PDAs,
electronic medical records, medical education, and timely access to diagnostic studies and spe-
cialists.
Clearly those of us  working in jails and prisons face enormous challenges as we attempt to pro-
vide legally defensible treatment to those entrusted to our care.  We have been tasked with pro-
viding complex medical care to a population that is disproportionately affected by severe chron-
ic conditions such as HIV, TB, hepatitis, substance abuse, and mental illness. We must never
stop challenging those who put our patients' lives and our professional reputations at risk by
denying us the tools necessary to accomplish the mission that has been given us. Martin Luther
King once said, "Our lives begin to end the moment that we become silent about things that mat-
ter." My less poetic version is that if we as correctional health care providers are not angry at
least once a day, we probably don't care enough about what we are doing.
- Joseph Bick
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nity HIV care reported that an HIV special-
ist was "never" available to see patients at
the clinic/hospital where they worked.
Forty-three percent of corrections-based
respondents and 93% of community-based
respondents reported that an HIV specialist
was "often" available to see patients at the
facility where they worked (Figure 3). 
Clinical Tests
CD4+ cell count and HIV viral load testing
were also reported to be more frequently
available in community-based clinics/hospi-
tals as compared to correctional facilities
(Figure 4).  The greatest discrepancy in
testing availability was in plasma HIV viral
load testing. While 87% of community-
based clinicians reported access to this
assay, only 65% of corrections-based
providers reported that this test was avail-
able.
HAART 
Of the respondents involved with correc-
tions-based HIV care, 18% reported that
patients "never" experienced disruptions in
HAART, compared to 64% of respondents
involved with community-based HIV care
(Figure 5). Seventy-one percent of correc-
tions-based respondents reported that indi-
viduals "sometimes" experienced disrup-
tions in HAART; 11% reported that patients
"often" experienced disruptions. In contrast,
33% of respondents involved with commu-
nity-based HIV care reported that patients
"sometimes" experienced disruptions in
HAART; 3% indicated that patients "often"
experienced disruptions.
Mental Health and Substance Abuse
Services
Both substance abuse counseling and
mental health counseling were more avail-
able in the corrections-based HIV care set-
ting compared to the community clinics
(83% vs. 77%, and 100% vs. 97%, respec-
tively). 
HIV-Related Educational Services
In contrast, educational sessions/lectures
on HIV, HIV case management, up-to-date
HIV reading materials, dietary/nutritional
counseling, HIV education, social work ser-
vices, adherence counseling, and peer
education were all more available in the
community-based clinics and hospitals
(Figures 6 and 7). Thirty-four percent of
respondents involved with corrections-
based HIV care reported the existence of
educational sessions or lectures on HIV at
their facility, as compared to 83% of
respondents involved with community-
based HIV care. Only 32% of respondents
involved with corrections-based HIV care
reported peer education at their facility, as
compared to 64% of respondents involved
with community-based HIV care.  
Social Services
In the correctional setting, ancillary ser-
vices were relatively limited when com-
pared to community-based care.
Specifically, 60% of respondents involved
with corrections-based HIV care reported
the existence of HIV case management at
their facility, as compared to 97% of
respondents involved with community-
based HIV care (Figure 7).  Sixty-one per-
cent of respondents involved with correc-
tions-based HIV care reported that their
facility offered adherence counseling, as
compared to 97% of respondents involved
with community-based HIV care.
Respondents' Perceptions Regarding
Quality of Care
Half of the corrections-based respondents
believed that the HIV care available at the
facility where they worked was "somewhat
4
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Figure 3. HIV Specialist Availability 
Figure 4. Clinical Tests Availability 
Figure 6. Available HIV Education
Resources     
Figure 7. Ancillary HIV-related Services   
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Figure 5.  HAART Disruptions
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CROI, indisputably the most respected of
the domestic clinical HIV conferences, was
held last month a mile high into the atmos-
phere in Denver, Colorado.  Most agree
that this year's conference was notable not
only for the relatively low oxygen content of
the inspired air but also for the quality of the
data presented.  The following is a review
of major themes emerging from this confer-
ence, with an emphasis on data that cor-
rectional clinicians managing HIV infection
are most likely to find of interest.
The Changing Epidemiology of HIV
Infection in New York State Prisons
The sole presentation involving inmates at
the conference came from New York, the
state with the highest number of HIV-infect-
ed men and women in the U.S.1 Over
22,000 consecutive inmates entering four
intake facilities from 1988-2003 were sur-
veyed about their HIV status and injection
drug use.  During the course of the study,
the prevalence of HIV infection dropped by
74% in men and almost 40% in women.
However, while decreases in HIV infection
at prison entry were observed in African-
American, Hispanic and white men, among
women the prevalence of HIV did not
change in those who were African-
American - remaining at about 15%. There
was a striking decline in HIV prevalence at
prison entry among injection drug users.
From 1988 to 1992, almost half of male and
female injection drug users tested were
HIV-infected.  By 2003, the rate of HIV
seropositivity dropped to about 20% for
injection drug users of both genders.  
Summary: These data provide an impor-
tant longitudinal assessment of the chang-
ing epidemiology of HIV infection in a large
correctional system and suggest a potential
impact of prevention efforts targeting users
of injection drugs.  While the decline in
inmates self-reporting injection drug use
was encouraging, the unchanged rate of
HIV seropositivity among African-American
women requires more attention given the
rapid increase in infections in this group.
Lastly, it is remarkable that more data from
correctional sources were not presented at
the conference given the number of per-
sons with HIV infection living in prisons and
jails.  One hopes that corrections-based
clinicians and researchers are saving their
data for the World AIDS Conference this
summer.   
HIV Therapy: The Benefits of Starting
Early and Not Stopping
The current antiretroviral therapy guide-
lines recommend the delay of treatment ini-
tiation in asymptomatic individuals until the
CD4 cell count falls to at least 350/mm3.  A
major rationale for postponing therapy has
been the avoidance of treatment-related
toxicity. To determine whether the CD4 cell
count at the time HIV therapy was initiated
predicted select toxicities - peripheral neu-
ropathy, lipoatrophy and renal insufficiency
- investigators from the HIV Outpatient
Study (HOPS), a clinical cohort study from
outpatient clinics across the U.S., exam-
ined records from over 2,200 patients seen
at least twice from 1996 to mid-2005
2
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better" or "much better" than the HIV care
available in community-based clinics or
hospitals. Thirty-six percent thought the
care was "equal," and 14% thought it was
"somewhat worse" or "much worse."
Eighty-three percent of community-based
respondents felt that the HIV care available
at the clinic or hospital where they worked
was "somewhat better" or "much better"
than the HIV care available within correc-
tions while the remaining 17% felt the care
was "equal;" none felt it was "somewhat
worse" or "much worse." 
Discussion
As judged by the criteria for a standard of
high-quality HIV care (Table 1), there may
be important differences in the quality of
HIV care when comparing correctional facil-
ities to community-based clinics. Most strik-
ing were differences between the settings
in the experience of the HIV providers as
measured by number of HIV-infected
patients currently under care and years of
experience as an HIV healthcare provider.
Further, the absence of basic HIV testing
modalities, most notably HIV viral load test-
ing, in the sample of corrections-based clin-
icians was surprising and, if confirmed,
identifies an area that requires urgent
attention.
According to the survey results, HIV-infect-
ed prisoners experience greater disruptions
in HAART. As mentioned above this may be
multiply-determined; however, such inter-
ruptions in therapy can be deleterious
regardless of cause. Further, supportive
services, with the notable exception of
mental health care, were less commonly
reported as available in correctional set-
tings. It is likely that the availability of such
services in correctional facilities varies
widely by the type of facility (jail versus
prison), whether the facility is run by the
state or federal government or a private
healthcare company, and by the prevalence
of HIV infection at that facility.
Despite these reported differences in care
and services, the vast majority (86%) of
respondents in the correctional setting felt
that the care available at the facilities where
they worked was at least as good as or bet-
ter than that available outside of correc-
tions. In contrast, the perception of commu-
nity providers was almost the inverse, with
83% indicating they believed community
HIV care was superior to such care deliv-
ered in correctional settings. Respondents
may have compared in-custody care with
care received by patients after they are
released and not with care that is generally
available in clinics on the outside. Despite
the fact that good HIV care is available on
the outside, many former inmates do not
avail themselves of it when they leave. As
previous studies have shown, many former
inmates return to jail/prison with worse con-
trol of HIV disease than when they were
released, suggesting that they may not
have been able to integrate into the "out-
side" clinics.17
This survey was unable to address other
key aspects of HIV care. For example,
treatment and prevention of opportunistic
infections was not covered although such
care is a crucial element of HIV therapeu-
tics. Similarly, oral/dental health services
and ophthalmology were not included in the
list of HIV-related services. 
In addition, the survey was restricted in its
ability to probe for additional information
regarding the care being delivered. For
example, in asking, "Do HIV-infected
patients ever experience disruptions in their
HAART?" we did not search for the pre-
dominant factor causing the disruption.
Interruptions in HAART may have been a
consequence of patients' decisions not to
adhere to treatment, the unavailability of
medication, or a lack of continuous medical
care. While disruption in medication nega-
tively impacts treatment regardless of its
cause, a patient's refusal or inability to
adhere to his/her regimen is very different
in terms of identifying opportunities to
redress gaps in quality of HIV care than a
lack of access to medication.18 While such
additional data would be valuable to the
aims of this investigation, the survey was
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considered more likely to be completed if it
were brief and easy to answer.
In order to preserve anonymity, survey
respondents were not asked to identify the
name of the facility where they were
employed at the time of the survey; hence,
it is impossible to know whether the facility
was a prison or a jail. This may obscure dif-
ferences between these types of correc-
tional facilities in regards to the quality of
HIV care. Response bias may have been a
factor in respondent's answers. Although
surveys were anonymous, respondents
may have desired to portray the HIV care in
their own facilities in a positive manner.
Although the survey was administered at a
national conference, respondents were not
representative of every state. Only 33
states were represented in the responses
and, therefore, their responses cannot be
generalized to the nation as a whole. In
addition, the survey participants represent
a subset of correctional healthcare
providers who had chosen to attend the
national conference and their facilities may
have differed from those of their colleagues
who did not attend. 
Selection bias also could have occurred in
the sampling of the community-based
providers who were approached about the
survey, as recommendations from correc-
tions-based HIV providers were used to
determine which community-based organi-
zations to contact. Additionally, due to the
descriptive nature of this study and the rel-
atively small sample size of community-
based health care workers, statistical tests
of the significance of the comparisons were
not performed.
Finally, the survey results were inherently
limited because they did not reflect patients'
opinions. Discrepancies in patient and
provider perceptions of HIV care-which
inevitably exist-could not be detected by
the survey. 
Conclusions
As judged by the criteria for a standard of
high-quality HIV care (Table 1) and this
snapshot of medical services, the correc-
tional facilities surveyed do not meet exist-
ing, well-accepted standards of HIV care,
as reported by corrections-based health-
care providers. There is a perception
among community providers of poorer care
in the prison which cannot be substantiated
by the current study, but which does bear
further investigation. Additionally, the
results suggest that the standard of HIV
care in U.S. correctional facilities lags
behind the standard of HIV care in non-cor-
rectional healthcare settings where former
inmates receive care. For almost every sur-
vey question, responses showed apprecia-
bly better access to HIV services and clini-
cal tests in the community-based clinics.
The lack of access to some of these ser-
vices may lead to compromised health and
increased morbidity and mortality for incar-
cerated individuals. 
And finally, were the results of this very lim-
ited survey of provider perceptions to be
confirmed in future investigations, it would
raise serious concerns regarding the
infringement of inmates' constitutional
rights currently defined as the ability to
access the same level of care as is provid-
ed in the community. While the deficiencies
were not large, some of the aspects of care
that were missing would have large impact
on clinical outcomes. These critically impor-
tant aspects of HIV care that are "standard"
in the community, but not apparently stan-
dard in correctional settings, include
access to HIV expertise and to such routine
tests as CD4+ cell counts, viral load testing,
and genotype testing.  Even relatively low
cost interventions fall farther behind; the
lack of access to up-to-date HIV education-
al materials, peer education, and HIV edu-
cation in general, is troubling. Limited
patient education is a reflection of their lim-
ited access to educational materials in cor-
rectional settings, but it is a deficiency that
is easily addressed at low cost. Most trou-
bling of all is the observation that health-
care providers in these correctional settings
seem to be unaware that the standard of
HIV care, as judged by the factors exam-
ined, in their facilities appears to be inferior
to the standard of HIV care in non-correc-
tional settings. 
This survey should be considered a prelim-
inary evaluation, at best, due to the large
number of constraints on the study design.
Future investigations are needed to further
explore these findings and, in particular,
should focus on the determinants of HIV
treatment interruption in correctional facili-
ties, the availability of laboratory tests that
are considered essential to routine care in
the community, and the training of clinicians
providing HIV care in correctional settings.
The survey also appears to highlight the
importance of linkage to care in the com-
munity, following release. In addition, a
broader assessment of supportive services
in disparate correctional settings is required
to identify areas where the greatest needs
exist, yet are unmet.
Healthcare providers in correctional set-
tings undoubtedly face challenges unique
to their work environment. It is critical that
these clinicians be provided with the essen-
tial tools and resources necessary to pro-
vide quality treatment to HIV-infected
patients placed in their care. Studies
designed to address the most cost-effective
approaches to providing HIV care in the
correctional setting are needed to answer
some of these questions and to provide
some insight as to how best to use the lim-
ited resources available.
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Patients were stratified by CD4 cell count at
time of treatment initiation.   In addition,
patients were categorized by whether they
were receiving HAART more than or less
than 95% of the time following treatment ini-
tiation.  Mortality and incidence of oppor-
tunistic infections were lower when HAART
was started at higher CD4 counts and when
taken 95% or more of the time; increasing
benefits of HAART were even evident
among those starting therapy at CD4 cell
counts above 350/mm3.  
Less anticipated was the effect initiating
HAART at lower CD4 counts on the inci-
dence of the toxicities studied.  Of the 2,222
patients, 113 developed renal insufficiency,
301 developed neuropathy, and 176 lipoat-
rophy. The incidence of each of these con-
ditions was lower among patients initiating
HAART at higher CD4 counts.  In multivari-
ate analyses persons with higher pre-
HAART CD4 counts were consistently less
likely to develop any of these toxicities. In
addition, persons who took HAART at least
95% of time were less likely to develop
renal insufficiency and distal symmetrical
polyneuropathy; however, the reverse asso-
ciation was seen for lipoatrophy where
greater time on therapy, particularly with
d4T (Zerit) and possibly indinavir (Crixivan)
or nevirapine (Viramune), was associated
with greater risk.
Summary: These results suggest that
some of the most feared adverse effects of
HAART may be prevented by early treat-
ment initiation and maintenance of therapy
to prevent loss of virologic and immunolog-
ic success.  This conclusion jibes well with
the results of the SMART Study, a trial of a
strategy of HIV treatment conservation in
which participants had their HIV therapy
discontinued until CD4 counts fell to below
250/mm3 and again stopped when reaching
350/mm3(3).  Excess mortality and disease
progression were observed among those
randomized to the drug conservation arm.
Remarkably, severe renal, cardiovascular
and hepatic events were also more likely in
those who discontinued HIV therapy.  
The improved overall outcomes seen with
early treatment initiation in this study are
noteworthy and as therapies continue to
become more potent and better tolerated,
the tipping of the balance toward earlier
administration of HIV therapy is likely.  That
near continuous HAART was found to be
associated with better disease free survival
and virologic and immunologic outcomes
may have a direct bearing on correctional
HIV care in light of the challenges jails and
prisons often face in maintaining uninter-
rupted HIV therapy (see Main Article).
Tenofovir and the Kidney
Tenofovir (Viread, and a component of
Truvada) is a potent and convenient anti-
retroviral agent that has become increas-
ingly useful in the treatment of treatment-
naïve and -experienced patients.  It has
been well appreciated that tenofovir can
cause renal impairment in some patients,
especially when the drug is not dose-adjust-
ed for decreased creatinine clearance or
when it is co-administered with nephrotoxic
agents.  In a recent study by Gallant and
colleagues tenofovir was associated with to
a small but measurable decline in creatinine
clearance4.  Several poster presentations at
CROI also described changes in renal func-
tion among different clinical cohorts.  
In a Center for Disease Control and
Prevention (CDC) study of over 11,300
HIV+ patients with a glomerular filtration
rate (GFR) >90 as calculated by the simpli-
fied modified diet in renal disease (MDRD)
equation the drug was associated with an
increased risk of a GFR <90 mL/min5.
However, few of the patients experienced
greater than moderate impairment and mild,
moderate and severe impairment occurred
in 35.1%, 6.4% and 2.6%, respectively.
Lower CD4 cell count, hemoglobin, dia-
betes, and hypertension were predictive of
renal impairment.
In a cohort of almost 390 patients treated
with tenofovir at the University of
Washington, 108 had a decrease in renal
function as measured by MDRD and/or the
more commonly used Cockcroft-Gault
equation of creatinine clearance6.  However,
no data were presented on concomitant
nephrotoxic drugs and, again, there was no
control group.  Interestingly, 17 subjects
had a decline by Cockcroft-Gault alone, 55
by the MDRD alone, and 36 by both.  The
MDRD does not include weight and the
Cockcroft-Gault does not include race.
Increased age, didanosine (Videx), ampre-
navir (Agenerase), and white race were
found to have a greater risk of developing
renal dysfunction by one or both equations
in this study.   
A study from the Atlanta Veterans
Administration Medical Center used a com-
pletely different definition of renal impair-
ment among 222 patients receiving teno-
fovir
7
.  Renal toxicity required either a 50%
change in creatinine clearance by the
Cockcroft-Gault equation or hypophos-
phatemia (defined as any phosphate level
less than 2.0 mg/dL).  During the year fol-
lowing initiation of tenofovir, a 50% change
in creatinine clearance was observed in 4%
and hypophosphatemia in 13% of patients.
Once more, there was no comparator group
and no information provided on the persis-
tence of hypophosphatemia or concomitant
medications.
Summary: These studies indicate that
there are some patients who may experi-
ence declines in renal function while taking
tenofovir but the rate of moderate or serious
renal impairment across these investiga-
tions was very low.  Each of the studies suf-
fered from one or more serious flaws includ-
ing the lack of controls (changes in renal
function have been observed in treated
patients not taking tenofovir), selection bias
(tenofovir receiving patients are more likely
to be treatment-experienced and have more
advanced HIV disease), and the use of dif-
ferent estimates of renal function.  There
was little to suggest that use of tenofovir
should be modified.  For patients with mar-
ginal renal function, the use of dose-adjust-
ed tenofovir should be considered.
Monitoring of creatinine clearance by the
Cockcroft-Gault equation or MDRD (see
Resources for online calculators) can easily
be accomplished.
CROI REPORT...
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April 8-11, 2006 
Las Vegas, NV
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http://www.ncchc.org/edu-
cation/updates2006/lasve-
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American Correctional
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Charlotte, NC
Visit:
http://www.aca.org/confer-
ences/summer06/
XVI International AIDS
Conference
August 13-18, 2006
Toronto, Canada
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"Hepatitis B & C with HIV
Co-infection"
April 19, 2006
12:30-2:30 EST
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stream of last conference
available on-line
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ACHSA 2006
Multidisciplinary Training
Conference
May 11-13, 2006
Durham, North Carolina 
Visit: www.achsa.org
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California's New Director of Prison Healthcare
Has Unprecedented Authority
Robert Sillen, chief of Santa Clara County's health
department, has been appointed by a federal dis-
trict judge to assume control over the healthcare in
California's prisons.  According to the San Jose
Mercury News, Sillen will have almost complete
authority over prison healthcare issues, from hiring
and firing state employees to appropriating the
healthcare budget.  The appointment follows a
recent review that determined that California's
prison-based healthcare had not significantly
improved following settlement of a 2001 class-
action lawsuit filed by prisoners.  Both Roderick
Hickman, Secretary of Youth and Adult Corrections,
and Governor Schwartzenegger have pledged their
support for Sillen's work. (At press time, Secretary
Hickman tendered his resignation, citing a lack of
commitment for change from state government and
the powerful prison guard union.)
California has approximately 168,000 inmates,
whose prison-based healthcare has been
described by Sillen as comparable to "Third World"
conditions.  System failures, reported by court-
appointed experts, that Sillen says he will aim to
correct include doctors' refusal to treat patients they
believed were faking illness, extreme inattention to
very ill patients, poorly stocked pharmacies, and
examining rooms lacking sinks and medical equip-
ment [1].  According to the news report, Sillen will
face the challenge of recruiting doctors and nurses
to work in a system with a reputation for inept
healthcare, and where correctional officers and
wardens have historically determined which prison-
ers receive medical attention
1
. 
1
Ostrov BF, Bailey B.  Sweeping power for new director of prison
care. Mercury News.  February 15, 2006:1A.
Self-Report vs. Voluntary Testing in
Determining Inmates' HIV Status
Lyons et al. compared self-reported HIV status to
HIV status determined by voluntary testing among
352 drug users incarcerated at the Cook County
Jail in Chicago.  Participants were interviewed
about their HIV status and drug habits, and were
offered HIV testing and a physical examination.
One hundred ten participants (31%) accepted the
voluntary HIV test; 100% of test results were nega-
tive.  Seven participants (1.9%) reported during the
interview that they were HIV-positive; all seven
declined the voluntary HIV test.  Six of these seven
participants reported a history of injecting drugs,
and five (71%) reported having shared needles.
The authors conclude that those who indicate past
drug use should be offered HIV testing yet, given
the high prevalence of drug use among those incar-
cerated, offering HIV testing to all inmates seems
more pragmatic.   
The results underscored the challenge of voluntary
HIV testing in a correctional setting and the need for
greater exploration of the determinants of HIV test-
ing acceptance among inmates.
Citation:  Lyons T, Goldstein P, Kiriazes J. HIV in Correctional
Facilities: Role of
Self-Report in Case Identification.  AIDS Patient Care and STDs
2006;20(2):93-96..
HIV Care Costs Have Decreased
Over the past twenty-five years, the average annu-
al cost of caring for an HIV-infected individual has
decreased, approximately, from $100,000 to
$13,900-$36,500, depending on patients' CD4
counts.  HAART treatment, at roughly $10,500 per
year, is the major HIV care expenditure for HIV
patients with CD4 counts greater than 350, while
hospitalization expenses predominate for those
with lower CD4 counts.  
Ironically, the successes of HIV care cast doubt on
whether this pattern of decline will continue in the
near future.  As patents expire and generic forms
become available, the cost of antiretroviral drugs
may decline in the next several years.  Yet at the
same time, HIV patients who benefit from HAART
continue to live longer, thereby increasing the num-
ber of co-morbid conditions and complications of
HIV infection necessitating medical attention.
Mayer and Chaguturu
1
alert clinicians to the suc-
cesses of HIV treatment in the 21st century and
also to the continued need for highly trained HIV
specialists in an era of increasingly complicated
HIV infection.
Chen et al.
2 
note that only 2% of HIV care costs
(about $370 per patient per year) are attributable to
physician expenses.  This figure highlights inade-
quate support for HIV specialists who require certi-
fications and training-necessary, professional costs
that are not sufficiently covered by this 2% of
expenditures.  In an era when military expenses are
swallowing up federal money that could otherwise
support the programs that cover the majority of HIV-
related expenses-Ryan White Act programs and
Medicaid-physicians should anticipate cuts to their
federal reimbursement.
1
Mayer KH, Chaguturu S. Penalizing Success: Is
Comprehensive HIV Care Sustainable?  Clin Inf Dis. 2006 Apr
1;42(7):1011-3. Epub 2006 Feb 22.
2
Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL,
Cloud GA, Stone BK, Carter J, Call S, Pisu M, Allison J, Saag
MS. Distribution of Health Care Expenditures for HIV-Infected
Patients. Clin Infect Dis. 2006 Apr 1;42(7):1003-10. Epub 2006
Feb 22. 
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RESOURCES
American Academy of HIV Medicine website.
http://www.aahivm.org
Conference on Retroviruses and Opportunistic
Infections (CROI) website.  
http://www.retroconference.org
Online calculator for creatinine clearance
http://www.intmed.mcw.edu/clincalc/creatinine.html
Online calculator for MDRD 
http://www.nephron.com/mdrd/default.html
National Commission on Correctional Healthcare.
Management of persons with HIV infection. 2001
http://www.ncchc.org
New York State Department of Health AIDS
Institute. HIV clinical practice guidelines.
http://www.hivguidelines.org
AIDSinfo: A Service of the U.S. Department of
Health and Human Services. 2005.  http://aidsin-
fo.nih.gov or  http://www.hivatis.org
Stephenson B, Leone P. HIV Care in U.S. Prisons:
The Potential and Challenge. 2005;14(4). 
http://www.acria.org/treatment/treatment_edu_fallup-
date2005_challenge.html
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Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through February 28, 2006. 
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1.  Each of the following should be considered an essential com
ponent of HIV care in the U.S. EXCEPT:
A. HIV viral load testing
B. CD4 cell count testing 
C. Care by a board certified Infectious Diseases physician 
D. Availability of combination antiretroviral therapy
2.  Bernard and colleagues found which of the following in their 
survey:
A. Corrections-based respondents judged HIV care to be 
better in correctional facilities than in the community 
B. Community-based respondents judged HIV care to be 
better in the community than in correctional facilities 
C. HIV viral load testing was reportedly available in 100% 
of the correctional facilities surveyed
D. Corrections-based respondents reported less access to 
case management than community providers
E. All of the above
3.  Data from New York State's Department of Corrections on 
the epidemiology of HIV from 1988 to 2003 found which of 
the following:
A. The proportion of inmates entering the system with HIV 
infection has decreased
B. HIV infection rose in all racial and ethnic groups during 
the course of the study
C. There was a decline in the HIV prevalence among male 
and female inmates reporting injection drug use
D. A and B
E. A and C
4.  Recent data regarding tenofovir indicate that: 
A. Tenofovir can cause decreases in renal function when 
the dose of the drug is not appropriately adjusted for 
creatinine clearance
B. Tenofovir may be more likely to cause changes in renal 
function among treatment experienced patients with low 
CD4 cell counts
C. Although renal impairment in patients receiving tenofovir 
seems to be rare, all patients administered the drug 
should have renal function monitored using Cockcroft-
Gault or MDRD equations
D. All of the above
5.  In the HOPS study of the timing of HIV treatment initiation 
starting HIV therapy at a lower CD4 cell count and treatment 
interruption were associated with a higher risk of renal prob
lems and peripheral neuropathy (TRUE or False)?
A. True
B. False
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